Essentially, IRAK1 is implicated in the pathogenesis and tumor progression of multiple cancers, including breast cancer, hepatocellular carcinoma, T-acute lymphoblastic leukemia, activated B cell-like diffuse large B cell lymphoma, melanoma, Kaposi sarcoma, lung cancer, head and neck squamous carcinoma, endometrial carcinoma, and pancreatic cancer, among others [209,211,224,227,228]. Here, IRAK1 is linked to breast carcinoma.